{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T04:11:56Z","timestamp":1751429516449,"version":"3.41.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Bethune Medical Science Research Fund","award":["N128BS"],"award-info":[{"award-number":["N128BS"]}]},{"name":"the Open Project of Hubei Key Laboratory of Wudang Local Chinese Medicine Research","award":["WDCM2023013"],"award-info":[{"award-number":["WDCM2023013"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"DOI":"10.1186\/s40360-025-00962-8","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T11:53:25Z","timestamp":1751370805000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Development and validation of a risk prediction model for meropenem-related thrombocytopenia in patients with pulmonary infection"],"prefix":"10.1186","volume":"26","author":[{"given":"Xiao","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongqin","family":"Ke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianyong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanhong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenwen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huibin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"962_CR1","doi-asserted-by":"publisher","first-page":"100890","DOI":"10.1016\/j.drup.2022.100890","volume":"66","author":"A Upadhayay","year":"2023","unstructured":"Upadhayay A, Ling J, Pal D, Xie Y, Ping FF. Kumar A Resistance-proof antimicrobial drug discovery to combat global antimicrobial resistance threat. Drug Resist Updat. 2023;66:100890. https:\/\/doi.org\/10.1016\/j.drup.2022.100890.","journal-title":"Drug Resist Updat"},{"issue":"3","key":"962_CR2","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1111\/jcpt.13369","volume":"46","author":"NA Steffens","year":"2021","unstructured":"Steffens NA, Zimmermann ES, Nichelle SM. Brucker N meropenem use and therapeutic drug monitoring in clinical practice: a literature review. J Clin Pharm Ther. 2021;46(3):610\u201321. https:\/\/doi.org\/10.1111\/jcpt.13369.","journal-title":"J Clin Pharm Ther"},{"issue":"11","key":"962_CR3","doi-asserted-by":"publisher","first-page":"e0032122","DOI":"10.1128\/aac.00321-22","volume":"66","author":"AQ Truong","year":"2022","unstructured":"Truong AQ, Dao XC, Vu DH, Nguyen HA, Do THG, Tran NT, Pham HN, Bui VC, Trinh TA, Dang QT, Nguyen GB, Lipman J, Cotta MO, Roberts JA, et al. Optimizing meropenem in highly resistant Klebsiella pneumoniae environments: population pharmacokinetics and dosing simulations in critically ill patients. Antimicrob Agents Chemother. 2022;66(11):e0032122. https:\/\/doi.org\/10.1128\/aac.00321-22.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"962_CR4","doi-asserted-by":"publisher","first-page":"R206","DOI":"10.1186\/cc10441","volume":"15","author":"J Gon\u00e7alves-Pereira","year":"2011","unstructured":"Gon\u00e7alves-Pereira J, P\u00f3voa P. Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of \u03b2-lactams. Crit Care. 2011;15(5):R206. https:\/\/doi.org\/10.1186\/cc10441.","journal-title":"Crit Care"},{"issue":"6","key":"962_CR5","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1016\/j.xphs.2022.01.015","volume":"111","author":"J Lan","year":"2022","unstructured":"Lan J, Wu Z, Wang X, Wang Y, Yao F, Zhao BX, et al. Chen C population pharmacokinetics analysis and dosing simulations of meropenem in critically ill patients with pulmonary infection. J Pharm Sci. 2022;111(6):1833\u201342. https:\/\/doi.org\/10.1016\/j.xphs.2022.01.015.","journal-title":"J Pharm Sci"},{"issue":"1","key":"962_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13256-020-02632-1","volume":"15","author":"K Hussain","year":"2021","unstructured":"Hussain K, Salat MS, Mohammad N, Mughal A, Idrees S, Iqbal J, et al. Meropenem-induced pancytopenia in a preterm neonate: a case report. J Med Case Rep. 2021;15(1):25. https:\/\/doi.org\/10.1186\/s13256-020-02632-1.","journal-title":"J Med Case Rep"},{"issue":"12","key":"962_CR7","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.18203\/2319-2003.ijbcp20195294","volume":"8","author":"P Dhande","year":"2019","unstructured":"Dhande P, Deshmukh S. Acute thrombocytopenia due to meropenem: a case report. Int J Basic Clin Pharmacol. 2019;8(12):2766\u20138. https:\/\/doi.org\/10.18203\/2319-2003.ijbcp20195294.","journal-title":"Int J Basic Clin Pharmacol"},{"issue":"9","key":"962_CR8","doi-asserted-by":"publisher","first-page":"e243443","DOI":"10.1136\/bcr-2021-243443","volume":"14","author":"J Cachia","year":"2021","unstructured":"Cachia J, Torpiano P, Pace D. Meropenem-induced thrombocytopenia: a paediatric case. BMJ Case Rep. 2021;14(9):e243443. https:\/\/doi.org\/10.1136\/bcr-2021-243443.","journal-title":"BMJ Case Rep"},{"issue":"7","key":"962_CR9","doi-asserted-by":"publisher","first-page":"498","DOI":"10.3760\/cma.j.cn112138-20200424-00419","volume":"59","author":"JX Wang","year":"2020","unstructured":"Wang JX, Zhang FC, Liu XQ, Tang CW, Chen LA, Han Y. Expert consensus for diagnosis and treatment of thrombocytopenia in China. Chin J Intern Med. 2020;59(7):498\u2013510. https:\/\/doi.org\/10.3760\/cma.j.cn112138-20200424-00419.","journal-title":"Chin J Intern Med"},{"issue":"3","key":"962_CR10","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.htct.2019.07.004","volume":"42","author":"LS Lima","year":"2020","unstructured":"Lima LS, Brito E, Mattos K, Parisotto EB, Perdomo RT, Weber SS. A retrospective cohort study to screen linezolid-induced thrombocytopenia in adult patients hospitalized in the Midwestern region of Brazil. Hematol Transfus Cell Ther. 2020;42(3):230\u20137. https:\/\/doi.org\/10.1016\/j.htct.2019.07.004.","journal-title":"Hematol Transfus Cell Ther"},{"issue":"2","key":"962_CR11","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/bcpt.13123","volume":"124","author":"GW Choi","year":"2019","unstructured":"Choi GW, Lee JY, Chang MJ, Kim YK, Cho Y, Yu YM, et al. Risk factors for linezolid-induced thrombocytopenia in patients without haemato-oncologic diseases. Basic Clin Pharmacol Toxicol. 2019;124(2):228\u201334. https:\/\/doi.org\/10.1111\/bcpt.13123.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"6","key":"962_CR12","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.3390\/nu12061760","volume":"12","author":"B Ed Nignpense","year":"2020","unstructured":"Ed Nignpense B, Chinkwo KA, Blanchard CL, Santhakumar AB. Black Sorghum phenolic extract modulates platelet activation and platelet microparticle release. Nutrients. 2020;12(6):1760. https:\/\/doi.org\/10.3390\/nu12061760.","journal-title":"Nutrients"},{"issue":"5","key":"962_CR13","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1097\/HJH.0b013e328345023d","volume":"29","author":"BJ van den Born","year":"2011","unstructured":"van den Born BJ, L\u00f6wenberg EC, van der Hoeven NV, de Laat B, Meijers JC, Levi M, et al. Endothelial dysfunction, platelet activation, thrombogenesis and fibrinolysis in patients with hypertensive crisis. J Hypertens. 2011;29(5):922\u20137. https:\/\/doi.org\/10.1097\/HJH.0b013e328345023d.","journal-title":"J Hypertens"},{"issue":"4","key":"962_CR14","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1093\/ajh\/hpt153","volume":"27","author":"E Gkaliagkousi","year":"2014","unstructured":"Gkaliagkousi E, Gavriilaki E, Yiannaki E, Markala D, Papadopoulos N, Triantafyllou A, et al. Douma S platelet activation in essential hypertension during exercise: pre- and post-treatment changes with an angiotensin II receptor blocker. Am J Hypertens. 2014;27(4):571\u20138. https:\/\/doi.org\/10.1093\/ajh\/hpt153.","journal-title":"Am J Hypertens"},{"issue":"6","key":"962_CR15","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1056\/NEJMra066469","volume":"357","author":"RH Aster","year":"2007","unstructured":"Aster RH, Bougie DW. Drug-induced immune thrombocytopenia. N Engl J Med. 2007;357(6):580\u20137. https:\/\/doi.org\/10.1056\/NEJMra066469.","journal-title":"N Engl J Med"},{"issue":"2","key":"962_CR16","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1111\/jcpt.12614","volume":"43","author":"F Mousinho","year":"2018","unstructured":"Mousinho F, Mendes T, Sousa ESP, Azevedo AP, Mousinho G, Malcata C, et al. Lima F Bisoprolol-induced thrombocytopenia: A case report. J Clin Pharm Ther. 2018;43(2):280\u20133. https:\/\/doi.org\/10.1111\/jcpt.12614.","journal-title":"J Clin Pharm Ther"},{"issue":"10","key":"962_CR17","first-page":"2025","volume":"32","author":"Z Juan","year":"2017","unstructured":"Juan Z, Yang Y. Literature analysis of thrombocytopenia caused by antibiotics. Drugs Clin. 2017;32(10):2025\u201330.","journal-title":"Drugs Clin"},{"issue":"4","key":"962_CR18","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1046\/j.1365-2141.1996.d01-1952.x","volume":"95","author":"G Ruiz-Irastorza","year":"1996","unstructured":"Ruiz-Irastorza G, Barreiro G, Aguirre C. Reversible bone marrow depression by high-dose piperacillin\/tazobactam. Br J Haematol. 1996;95(4):611\u20132. https:\/\/doi.org\/10.1046\/j.1365-2141.1996.d01-1952.x.","journal-title":"Br J Haematol"},{"issue":"2","key":"962_CR19","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1136\/ejhpharm-2022-003258","volume":"31","author":"Y Qin","year":"2024","unstructured":"Qin Y, Chen Z, Gao S, Shen Y, Ye YR. Development and validation of a risk prediction model for linezolid-induced thrombocytopenia in elderly patients. Eur J Hosp Pharm. 2024;31(2):94\u2013100. https:\/\/doi.org\/10.1136\/ejhpharm-2022-003258.","journal-title":"Eur J Hosp Pharm"},{"issue":"24","key":"962_CR20","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.13286\/j.1001-5213.2020.24.09","volume":"40","author":"Y Shen","year":"2020","unstructured":"Shen Y, Qin Y, Chen Z, Dai PF, Lu QZ, Li XY, et al. Logistic model combined with ROC curve to predict linezolid-induced thrombocytopenia in elderly patients. J Pharm China Hosp. 2020;40(24):2544\u20138. https:\/\/doi.org\/10.13286\/j.1001-5213.2020.24.09.","journal-title":"J Pharm China Hosp"},{"issue":"11","key":"962_CR21","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1111\/trf.14267","volume":"57","author":"R Huang","year":"2017","unstructured":"Huang R, Cai GQ, Zhang JH, Liu FX, Ma JQ, Liu H, et al. Meropenem-induced immune thrombocytopenia and the diagnostic process of laboratory testing. Transfusion. 2017;57(11):2715\u20139. https:\/\/doi.org\/10.1111\/trf.14267.","journal-title":"Transfusion"},{"key":"962_CR22","first-page":"1503","volume":"27","author":"MU Khan","year":"2014","unstructured":"Khan MU, Yousuf RI, Shoaib MH. Drug utilization evaluation of meropenem and correlation of side effects with renal status of patients in a teaching based hospital. Pak J Pharm Sci. 2014;27:1503\u20138.","journal-title":"Pak J Pharm Sci"},{"issue":"08","key":"962_CR23","first-page":"777","volume":"46","author":"YX Liu","year":"2021","unstructured":"Liu YX, Liu TT, Wei G, Yan P, Fang XQ, Xie LX. Analysis of risk factors of linezolid-related thrombocytopenia and establishment of risk prediction model. J PLA Med. 2021;46(08):777\u201382.","journal-title":"J PLA Med"},{"issue":"14","key":"962_CR24","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.13286\/j.cnki.chinhosppharmacyj.2019.14.14","volume":"39","author":"YH Zhang","year":"2019","unstructured":"Zhang YH, Li Y, Lei Z, Qiu J, Shi TL. Study on risk factors of linezolid-induced thrombocytopenia by TDM combined with logistic model. China Hosp Pharm J. 2019;39(14):1485\u20138. https:\/\/doi.org\/10.13286\/j.cnki.chinhosppharmacyj.2019.14.14.","journal-title":"China Hosp Pharm J"},{"issue":"1","key":"962_CR25","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/jcpt.12762","volume":"44","author":"HS Kim","year":"2019","unstructured":"Kim HS, Lee E, Cho YJ, Lee YJ, Rhie SJ. Linezolid-induced thrombocytopenia increases mortality risk in intensive care unit patients, a 10 year retrospective study. J Clin Pharm Ther. 2019;44(1):84\u201390. https:\/\/doi.org\/10.1111\/jcpt.12762.","journal-title":"J Clin Pharm Ther"},{"issue":"10","key":"962_CR26","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.14009\/j.issn.1672-2124.2021.10.028","volume":"21","author":"XM Guo","year":"2021","unstructured":"Guo XM, Wang Y, Liu N, Meng HX, Wang JR, Cui CB. Analysis of risk factors of thrombocytopenia caused by Cefoperazone sodium and sulbactam sodium. Evaluation Anal Drug Use China Hosp. 2021;21(10):1273\u20136. https:\/\/doi.org\/10.14009\/j.issn.1672-2124.2021.10.028.","journal-title":"Evaluation Anal Drug Use China Hosp"},{"issue":"3","key":"962_CR27","doi-asserted-by":"publisher","first-page":"306","DOI":"10.19803\/j.1672-8629.2022.03.16","volume":"19","author":"CC Chen","year":"2022","unstructured":"Chen CC, Tan RJ, Wang LD, Zhang YY, Hu XY, Chen YY. Analysis of clinical characteristics and risk factors of thrombocytopenia caused by fluoroquinolones. Pharmacovigil China. 2022;19(3):306\u20139. https:\/\/doi.org\/10.19803\/j.1672-8629.2022.03.16.","journal-title":"Pharmacovigil China"},{"key":"962_CR28","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.thromres.2020.03.012","volume":"190","author":"C Liu","year":"2020","unstructured":"Liu C, Cheng L, Ji L, Li F, Zhan Y, Wu B, et al. Intestinal microbiota dysbiosis play a role in pathogenesis of patients with primary immune thrombocytopenia. Thromb Res. 2020;190:11\u20139. https:\/\/doi.org\/10.1016\/j.thromres.2020.03.012.","journal-title":"Thromb Res"},{"issue":"1","key":"962_CR29","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.cell.2016.02.011","volume":"165","author":"W Zhu","year":"2016","unstructured":"Zhu W, Gregory JC, Org E, Buffa JA, Gupta N, Wang Z, McIntyre TM, Silverstein RL, Tang WHW, DiDonato JA, Brown JM, Lusis AJ, Hazen SL, et al. Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk. Cell. 2016;165(1):111\u201324. https:\/\/doi.org\/10.1016\/j.cell.2016.02.011.","journal-title":"Cell"},{"key":"962_CR30","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3389\/fnut.2016.00042","volume":"3","author":"ZL Liao","year":"2016","unstructured":"Liao ZL, Zeng BH, Wang W, Li GH, Wu F, Wang L, et al. Impact of the consumption of tea polyphenols on early atherosclerotic lesion formation and intestinal bifidobacteria in High-Fat-Fed ApoE-\/-Mice. Front Nutr. 2016;3:42. https:\/\/doi.org\/10.3389\/fnut.2016.00042.","journal-title":"Front Nutr"},{"issue":"6","key":"962_CR31","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1182\/blood-2016-03-708594","volume":"129","author":"KS Josefsdottir","year":"2017","unstructured":"Josefsdottir KS, Baldridge MT, Kadmon CS, King KY. Antibiotics impair murine hematopoiesis by depleting the intestinal microbiota. Blood. 2017;129(6):729\u201339. https:\/\/doi.org\/10.1182\/blood-2016-03-708594.","journal-title":"Blood"},{"issue":"4","key":"962_CR32","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/cpt.1866","volume":"108","author":"J Sun","year":"2020","unstructured":"Sun J, Deng X, Chen X, Huang J, Huang S, Li Y, et al. Incidence of adverse drug reactions in COVID-19 patients in china: an active monitoring study by hospital pharmacovigilance system. Clin Pharmacol Ther. 2020;108(4):791\u20137. https:\/\/doi.org\/10.1002\/cpt.1866.","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"962_CR33","doi-asserted-by":"publisher","first-page":"e567","DOI":"10.1016\/S2352-3026(24)00139-X","volume":"11","author":"Y Hu","year":"2024","unstructured":"Hu Y, Liu X, Zhou H, Wang S, Huang R, Wang Y, et al. Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Haematol. 2024;11(8):e567\u201379. https:\/\/doi.org\/10.1016\/S2352-3026(24)00139-X.","journal-title":"Lancet Haematol"},{"issue":"04","key":"962_CR34","first-page":"964","volume":"48","author":"J Zhang","year":"2025","unstructured":"Zhang J, Hao LN. Warning signal mining of drug-induced thrombocytopenia in children based on American FAERS database. Drug Evaluation Res. 2025;48(04):964\u201370.","journal-title":"Drug Evaluation Res"},{"issue":"3","key":"962_CR35","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1055\/s-0039-1697930","volume":"46","author":"E Danese","year":"2020","unstructured":"Danese E, Montagnana M, Favaloro EJ, Lippi G. Drug-Induced thrombocytopenia: mechanisms and laboratory diagnostics. Semin Thromb Hemost. 2020;46(3):264\u201374. https:\/\/doi.org\/10.1055\/s-0039-1697930.","journal-title":"Semin Thromb Hemost"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-00962-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-025-00962-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-00962-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T11:53:29Z","timestamp":1751370809000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-025-00962-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["962"],"URL":"https:\/\/doi.org\/10.1186\/s40360-025-00962-8","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"15 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The studies involving humans were approved by the Ethics Committees of Shiyan Renmin Hospital (Ethics number: syrmyy2023-011); Ethics Committees of Shiyan Taihe Hospital (Ethics number:2024KS64). The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation was not required from the participants or the participants\u2019 legal guardians\/next of kin in accordance with the national legislation and institutional requirements.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"127"}}